Brief: Modeyso™ (dordaviprone) Added to NCCN Guidelines for H3 K27M-Mutant Diffuse Glioma
09/09/2025 12:46
Sept 9 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O: MODEYSO™ (DORDAVIPRONE) INCLUDED IN NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR H3 K27M-MUTANT DIFFUSE GLIOMA Source text: ID:nPn7tp6hqa Further company coverage: JAZZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032